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Purpose: The purpose of this study was to investigate the acute toxic potential of cerium oxide 
nanoparticles (CNPs) synthesized by pullulan in adult male Wistar rats.
Patients and methods: Thirty male Wistar rats randomly were divided into five experimental 
groups of six animals each. The animals were received 50, 100, 200, and 400 mg/kg CNPs for 14 
consecutive days. At the end of the experiment, the rats were euthanized and histopathological 
evaluation of the liver and renal tissues, as well ass, the markers of serum oxidative stress includ-
ing thiobarbituric acid reactive substances, total sulfhydryl content, and antioxidant capacity 
(using ferric reducing/antioxidant power assay) were assessed. Hematological parameters and 
the activity of liver function enzymes were also measured.
Results: The results of this study showed that CNPs caused no significant changes in the activ-
ity of liver enzymes, hepatic and renal histopathology and hematological parameters, while 
significantly improved serum redox status.
Conclusion: Acute administration of pullulan-mediated CNPs is safe and possess antioxidant 
activity.
Keywords: green synthesis, metal oxide, sol-gel, toxicology, radical scavenger
Introduction
In the last few decades, nanotechnology has been employed throughout biomedical 
research studies.1–3 Cerium oxide nanoparticles (CNPs), consisting of cerium atoms 
linked by oxygen atoms, have been used in commercial, industrial, and biological 
applications.4–6 CNPs are considered as one of the most interesting nanomaterials due 
to their catalytic attributes and seem to be practical in therapy applications.7,8 Further-
more, these nanoparticles are extensively employed for producing oxygen sensors,9 
automotive catalytic converters,10 and so on. Pullulan, a unique natural material, is a 
water-soluble polysaccharide that could be used in various biomedical/bioengineer-
ing applications due to its non-toxic, non-immunogenic, non-mutagenic, and non-
carcinogenic nature.11,12 In our pervious study, we have prepared ceria nanoparticles 
by using pullulan as a capping agent that could affect the morphology of CNPs. In fact, 
the presence of hydroxyl groups in the backbone would provide a medium that would 
interact effectively with cationic cerium ions.13 It was illustrated from the cytotoxic-
ity results that CNPs have no toxicity against Neuro2A cells of ,125 μg/mL.14 The 
disease progression of many neurodegenerative conditions is strongly related to the 
oxidative damage that is caused by increasing the generation of reactive oxygen spe-
cies (ROS).15 Nowadays, the antioxidant properties of CNPs have been discovered to 
be throughout the Ce3+/Ce4+ redox reaction on the surface of nanoparticles,4,16 which 
could be beneficial in biomedical applications and protect cells from damage due to 
radiation, oxidative stress, or inflammation.17 Since CNPs are capable of stimulating 
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the catalytic potency of superoxide dismutase (SOD),18 it 
could be applied as a potent antioxidant. Redox properties 
of CNPs could also detoxify the existing free radicals for 
prolonged time intervals by maintaining its bioactivity within 
the tissues.19 The main objective of this work was to evaluate 
the effects of biosynthesized CNPs on oxidative stress status 
and biochemical and hematological parameters, along with 
the histopathological alterations in adult male Wistar rats.
Materials and methods
cNP synthesis and its cytotoxicity
CNPs were prepared from a previously reported method.14 






O (10.1 g) was 
dissolved in double distilled water (ddH
2
O, 25 mL) and 
stirred for 30 minutes. Then, dissolved pullulan (1.5 g in 
50 mL ddH
2
O) was added at 60°C with string for 8 hours. 
Finally, the obtained resin was calcined (rate: 3°C/min) at 
500°C for 2 hours. The CNPs were characterized by FTIR 
(Figure S1), FESEM (Figure S2), and X-ray diffraction 
(XRD) (Figure S3). Cell viability of CNPs was determined 
by MTT assay against Neuro2A cells as described in the 
literature.14 The detailed procedure is provided in the Supple-
mentary materials. The absorbance of the amount of forma-
zan formation was measured by a plate reader (statfax303) 
at λ
max
 =570 and 620 nm (Figure S4).
animals and experimental procedure
We obtained male Wistar rats (weighing 200–230 g) from the 
Animal Center of School of Medicine, Mashhad University 
of Medical Sciences (MUMS), Mashhad, Iran. Then, they 
were provided with accommodations, which included housing 
and constant temperature (22°C±2°C), as well as the standard 
conditions of 12 hour light/dark cycle and free access to food 
pellets and tap water. The rats had been allowed to acclimatize 
for 1 week prior to the testing process. All the designated rats 
were handled in conformity with the National Institutes of 
Health Guidance for Care and Use of Laboratory Animals, 
while the Animal Ethics Committee of MUMS had authorized 
their usage for this particular project. The procedure was 
performed in five separate groups, each comprising six rats 
divided randomly. Animals in the experimental groups have 
been treated intraperitoneally with CNPs in order to obtain 50, 
100, 200, and 400 mg/kg in 14 consecutive days. The negative 
control group has been injected with normal saline for 14 days.
laboratory analyses
The anesthetizing process has been carried out by using ket-
amine and xylazine on the rats subsequent to the passage of the 
14-day experiment in animal laboratory of MUMS, Faculty of 
Medicine. The blood samples were collected from the abdomi-
nal aorta and were accumulated and kept within sterile tubes 
with an anticoagulant (K3-EDTA) in order to investigate the 
hematological parameters. Non-anticoagulant was used in bio-
chemical testing procedures such as alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), lactate dehydroge-
nase (LDH), alkaline phosphatase (ALP), glucose, urea, cre-
atinine (Cr), and direct and total bilirubin (Bill-D/T) by using 
the related commercial kits and a Biotecnica BT-3500 chem-
istry analyzer (Diamond Diagnostics, Holliston, MA, USA).20 
After blood serums were separated by centrifuge, they were 
analyzed by Biotechnica BT-3500 chemistry analyzer (Dia-
mond Diagnostics; USA) using glucose, Cr, Bill-D/T, urea, 
AST, ALT, ALP and LDH reagents. The experimental assays 
were performed at a commercial laboratory (Laboratory of 
Modern Sciences and Technology Department at Mashhad 
University of Medical Sciences) using Man company kits in 
Iran under license of ELItech group, France. The detailed 
protocols could be obtained from the Man Company website 
(http://mancompany.com/en/; in biochemistry products). 
Routine hematological parameters including white blood 
cell (WBC) count, red blood cell (RBC) count, hemoglobin 
(Hb) concentration, hematocrits (HTC), mean corpuscular 
volume (MCV), platelet (PLT) count, and RBC distribution 
width (RDW) have been determined by the application of 
a blood cell counter (Sysmex KX-21N™; Sysmex, Hyogo, 
Japan). Serum was used for evaluating malondialdehyde 
(MDA), SOD activity, total sulfhydryl (SH) groups, catalase 
activity, and ferric reducing/antioxidant power (FRAP). The 
results were analyzed by one-way ANOVA using GraphPad 
Prism version 6.01 (GraphPad Software, Inc., La Jolla, CA, 
USA). Data were expressed as mean ± SEM, and values were 
considered statistically significant at P,0.05. The protocol 
was confirmed by the Animal Use and Care Advisory Com-
mittee of MUMS.
histopathological examination
After collecting the blood samples, the rats were euthanized 
and the liver and kidney tissues were removed and fixed in 10% 
formalin. After mounting, a 5 μm section of each tissue was pre-
pared and then stained with H&E. Histopathological changes 
were then investigated and blindly scored by a pathologist.21,22
Measurement of MDa
The levels of MDA, as the final product of lipid peroxidation 
process, were determined using thiobarbituric acid (TBA), as 
the reagent.23,24 Briefly, 100 μL of serum was mixed with 2 mL 
of TCA-TBA-HCl reagent (15% trichloroacetic acid, 0.67% 
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water bath. After cooling, the mixture was centrifuged at 
3,000 rpm for 10 minutes. The supernatant was collected, and 
the absorbance was read against the blank reagent at 532 nm. 
The amount of MDA produced was calculated in μmol/L.23
Determination of sOD activity
SOD activity in serum was evaluated using a spectropho-
tometric method.25 Briefly, the sample was incubated in a 
solution containing Tris-HCl buffer (pH 8.2, 50 mM) and 
EDTA (1 mM). Reaction was initiated by the addition of 
0.2 mM pyrogallol. Oxidation of pyrogallol was measured 
at 420 nm for 10 minutes, at intervals of 1 minute. The per-
centage inhibition of pyrogallol autoxidation was determined 
using the following equation:
 




















where ΔA stands for absorbance change due to pyrogallol autox-
idation in the sample reaction system, and ΔA
max
 represents the 
absorbance change that is induced by pyrogallol autoxidation 
in the control (without homogenate sample). A 50% inhibition 
was interpreted as one unit (U) of SOD activity.25
assay of total sh groups
Total SH groups were measured using 5,5′-dithiobis-
2-nitrobenzoic acid (DTNB).26 Briefly, 1 mL of Tris-EDTA 
buffer (pH 8.6) was added to 50 μL of serum and 50 μL of 
the sample. The sample absorbance was observed at 412 nm 
against Tris-EDTA buffer (A1). Afterward, 20 μL of DTNB 
reagent (10 mM in methanol) was added to the mixture and, 
after 15 minutes, the sample absorbance was read again (A2). 
Moreover, the absorbance of DTNB reagent was read as a 
blank (B). Total thiol concentration (mM) was determined 
using the following equation:
 
Total thiol concentration (mM) 








assay of catalase activity




) by catalase 





bance at 240 nm. The difference in absorbance per unit 
time is a measure of catalase activity. The results obtained 
for the sample containing 500 μL of serum and 500 μL of 




 prepared in 50 mM 
phosphate buffer, pH 7.0) were compared with those of a 
blank containing 500 μL of phosphate buffer, instead of 
substrate solution, and 500 μL of sample. The reaction was 
initiated by adding the substrate solution and the solution 
was incubated at 20°C for 1 minute. Catalase activity was 




/min/mg protein (U/L). An enzyme 
unit has been defined as the quantity of enzymes that can 




 per minute at the 
temperature of 20°C. Specific activity has been measured 
with reference to units per milligram of protein.27
assay of FraP
The serum antioxidant (reducing) power was measured using 
the FRAP assay.26 Briefly, 50 μL of serum was added to 
1.5 mL of freshly prepared and pre-warmed (37°C) FRAP 
reagent (300 mM acetate buffer, 10 mM TPTZ in 40 mM 
HCl, and 20 mM FeCl
3
 in the ratio of 10:1:1) in a test tube 
and incubated at 37°C for 8 minutes. The optical density of 
the blue colored complex was read against the blank reagent 
at 593 nm. The data were expressed as μmol of ferric ions 
reduced to ferrous form per liter (FRAP-value).26
Results
effect of cNPs on hematological 
parameters
As it is illustrated in Table 1, there has been no significant 
changes in the WBC, RBC, HCT, Hb, PLT, MCV, and RDW 
indices in all of the experimental groups in comparison with 
the control group (P.0.05 for all).
effect of cNPs on biochemical markers
According to the obtained data (Table 2), significant differ-
ences in serum BS, urea, Cr, Bill-D, and Bill-T levels, as 
well as the ALP, LDH, AST, and ALT activities were seen 




The liver tissue was investigated for the existence of any 
pathological changes such as inflammatory reactions, necrosis, 
apoptosis, and fibrosis in different liver zones, ports, and 
regional centrilobular space. Light microscopic evaluation of 
liver tissue in all the doses of CNPs did not display any notable 
variation in comparison with the control (Figure 1A, P.0.05).
Kidney
Structural changes in the renal glomerular tubules and vessels 
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Table 1 effect of cNPs on hematological parameters in male Wistar rats
Parameters Control CNPs 50 CNPs 100 CNPs 200 CNPs 400 P-value
WBc (×103/μl) 5.30±0.41 6.32±0.43 6.84±0.36 7.06±0.27 7.00±0.41 Ns
rBc (×106/μl) 8.18±0.08 7.50±0.22 7.60±0.19 7.30±0.15 7.43±0.25 Ns
hcT (%) 54.3±0.16 43.8±1.27 44.2±0.65 42.6±0.98 42.9±1.45 Ns
hb (g/dl) 14.7±0.06 14.2±0.29 14.3±0.21 13.8±0.27 13.8±0.51 Ns
PlT (×103/μl) 262.6±24.8 223.6±20.98 251±42.67 254.6±24.47 249.2±23.02 Ns
McV (fl) 53.5±0.22 56.2±2.29 57.2±0.35 58±0.38 57.42±0.34 Ns
rDW (fl) 13.18±0.10 13.82±0.84 13.60±0.16 14.32±0.48 13.08±0.27 Ns
Abbreviations: cNPs, cerium oxide nanoparticles; WBc, white blood cell count; rBc, red blood cell count; hb, hemoglobin concentration; hTc, hematocrits; McV, mean 
corpuscular volume; PLT, platelet count; RDW, RBC distribution width; NS, not significant.
Table 2 Biochemical serum profile of male Wistar rats after 14 days exposure to CNPs
Parameters Control CNPs 50 CNPs 100 CNPs 200 CNPs 400 P-value
glucose (mg/dl) 85.2±3.5 89.4±5.8 78±5.5 80±5 92.8±7.4 Ns
Urea (mg/dl) 38.8±1.50 39.2±1.65 40.8±1.8 38.20±1.35 40±1.22 Ns
cr (mg/dl) 0.68±0.026 0.72±0.02 0.7±0.03 0.7±0.028 0.7±0.022 Ns
Bill-D (mg/dl) 0.036±0.005 0.034±0.005 0.034±0.005 0.30±0.003 0.032±0.004 Ns
Bill-T (mg/dl) 0.25±0.02 0.22±0.03 0.24±0.024 0.21±0.018 0.22±0.023 Ns
alP (IU/l) 77.4±6.30 81.8±9.2 83.4±9.68 71.6±6.20 80.2±6.12 Ns
lDh (IU/l) 81.2±8.96 84.6±7.1 80.8±10.20 71.6±6.20 88.8±7.99 Ns
asT (IU/l) 62.6±2.62 61.8±3.9 59.2±5.94 55.6±4.67 63.2±4.88 Ns
alT (IU/l) 26.4±1.03 27.8±1.2 22.8±1.77 26.2±1.53 24.6±1.54 Ns
Note: all values are expressed as mean ± standard error of the mean.
Abbreviations: cNPs, cerium oxide nanoparticles; alT, alanine aminotransferase; asT, aspartate aminotransferase; lDh, lactate dehydrogenase; alP, alkaline phosphatase; 
Cr, creatinine; Bill-D/T, direct and total bilirubin; NS, not significant.
no significant pathological changes (P.0.05) between the 
CNP-treated group and the control group (Figure 1B).
effect of cNPs on MDa level
Figure 2A shows that that CNP administration at doses 
of 50, 100, 200, and 400 mg/kg significantly (P,0.001 
for all) decreased the MDA level to 1.5±0.02, 1.5±0.03, 
1.5±0.03, and 1.5±0.02 μmol/L, as compared to control 
(1.9±0.02 μmol/L), respectively.
effect of cNPs on sOD level
As illustrated in Figure 2B, administration of CNPs resulted 
in significant increase in SOD activity in CNP-treated 
rats (27.4±0.4 U/L at 50 mg/kg, P,0.05; 28.0±0.6 U/L at 
100 mg/kg, P,0.01; 29.4±0.4 U/L at 200 mg/kg, P,0.001; 
and 29.8±0.6 U/L at 400 mg/kg, P,0.001), as compared to 
the control (24.7±0.5 U/L).28
effect of cNPs on sh level
As shown in Figure 2C, administration of CNPs at doses of 
50, 100, 200, and 400 mg/kg increased the total SH content 
to 15.6±0.3 mM (P,0.05), 15.6±0.8 mM (P,0.05), 
16.0±0.9 mM (P,0.01) and 16.3±0.5 mM (P,0.01) 
respectively, in comparison with control (12.3±0.5 mM).
effect of cNPs on caT level
As shown in Figure 2D, the administration of CNPs at doses 
of 50, 100, 200, and 400 mg/kg has caused an increase in 
the CAT level toward 30.6±2.4, 33.1±0.5, 32.9±1.2, and 
33.0±4.0 U/L, as compared to the control (23.0±0.7 U/L), 
respectively (P,0.05 for all).
effect of cNPs on FraP level
We have perceived a notable increase within the FRAP 
level following the administration of CNPs with doses of 
50 (653.3±22.12), 100 (659.8±12.55), 200 (659.0±9), and 
400 mg/kg (657.8±21.48) in comparison with the control 
(586.6±12), respectively (P,0.05 for all) (Figure 2E).
Discussion
Investigation of the effects of nanomaterials on cellular 
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of these materials in medical applications.10 Biochemical 
parameters have a significant role in determining toxicity 
because changes in their levels are considered as one of 
the best general indicator of the toxicity.29–31 Moreover, 
these particular biochemical tests can be easily carried 
out in most of the diagnostic laboratories.32 On the other 
hand, CNPs were known as antioxidants because of their 
dual redox states on the surface.33–35 Antioxidants could 
be harmful per se, because of pro-oxidant activity.36–38 For 
example, Srinivas et al suggested that acute exposure of 
CNPs through inhalation route may induce cytotoxicity via 
oxidative stress and may lead to a chronic inflammatory 
response.39 Adebayo et al also showed that administration 
of 100–300 mg/kg CNPs thrice in a week for 5 consecutive 
weeks to mice induces testicular dysfunction via disruption 
of antioxidant/oxidant balance and endocrine suppression.40
In compliance with our previous studies, CNPs were char-
acterized by FTIR, FESEM, and XRD. The results of charac-
terization were in good agreement with our previous report.14 
Nanoparticles can be potentially hazardous to the central 
nervous system because they can readily bypass or cross the 
blood–brain barrier.41–43 One of the limitations of our study is 
the lack of brain pathology data following CNP administra-
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Figure 1 (A, B) Histopathological findings in liver and kidney of male Wistar rats after treatment with CNPs for 14 days (H&E, 400×).
Abbreviation: cNPs, cerium oxide nanoparticles.
used for the evaluation of possible toxicity of CNPs, which 
showed low dose-toxicity under 500 μg/mL. Intraperitoneal 
administration is a commonly used technique to administer 
large quantity of medicine in small animals. Although it is 
parenteral route, but unlike intravenous injection, the drug 
delivery is much slower.44 Therefore, intravenous injection 
usually uses lower doses of nanoparticles that is usually 
under 5 mg/kg for CNPs,45–47 but in intraperitoneal injection, 
it is safer if higher doses were used.48 Herein, we want to 
show that CNPs are safe following acute administration. To 
evaluate the toxicity of the substances in vivo, CNPs were 
administered to rat and then some toxicological parameters 
such as histopathological parameters were evaluated and 
hematotoxicity analyses were performed. CNPs did not 
cause any vital alteration throughout the hematological and 
biochemical parameters of experimental groups relative to 
negative controls. In addition, histopathological examina-
tion of liver and kidney tissues, which were performed by 
using light microscopy technique, has not pointed out any 
notable pathological changes. This seems to be in parallel 
with the obtained normal results from biochemical param-
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Figure 2 effects of cNPs on serum oxidant/antioxidant status of male Wistar rats after treatment with cNPs for 14 days. (A) effect of cNPs on MDa level. (B) effect of 
cNPs on sOD activity. (C) effect of cNPs on total sh level. (D) effect of cNPs on caT activity. (E) effects of cNPs on FraP values are expressed as mean ± seM (n=7). 
*P,0.05, **P,0.01, ***P,0.0001 as compared with the control group.
Abbreviations: cNPs, cerium oxide nanoparticles; MDa, malondialdehyde; sOD, superoxide dismutase; sh, sulfhydryl; caT, catalase; FraP, ferric reducing/antioxidant 
power.
our results, Srinivas et al also reported that CNPs did not 
cause any harmful effects on liver and kidney functions or 
hematology or blood biochemistry of rats exposed to CNPs at 
14-day post exposure period.39 Furthermore, the measures of 
serum oxidative/anti-oxidative indices including MDA, SOD 
activity, SH groups, and the catalase (CAT) indices among all 
experimental doses in treated rats have a significant change in 
comparison with the control group, which have indicated that 
they can considerably effect on the potency of antioxidant. 
Antioxidant effects of CNPs may not be very obvious in 
healthy non-injured animals (ie, physiological conditions), 
but it has been reported that protective antioxidant effects 
are found under pathological conditions.49 On the other hand, 
according to the FRAP test on serums obtained from rats 
that had received CNPs, a stronger antioxidant activities in 
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agreement with other studies indicating the ability of CNPs to 
bind to oxygen under reducing and oxidizing circumstances, 
which plays a key role in neutralizing a variety of ROS.50,51 
CNPs have been so far applied for ameliorating the signs 
of several oxidative stress-based animal model’s diseases, 
including Alzheimer’s, cardiomyopathy, and cancers.10,52,53 
Indeed, the balance between the oxidant production and 
antioxidant content is pivotal for a correct cell function.54 
Therefore, anti-oxidant agents might have toxic or non-
toxic effects. In general, CNPs exhibited protective effects 
against oxidative stress, in vitro and in vivo.55,56 The cur-
rent research was carried out to exactly evaluate the safety/
toxicity of CNP (synthesized with pullulan) administration, 
as an anti-oxidant agent. The scientific databases revealed 
that there are several studies about the effects of CNPs on 
different types of cells. For instance, a study performed on 
the rat retina cells showed that nanoceria was found to be 
non-toxic.57 Similarly, the results of another study stated the 
non-toxicity of 2,000 mg/kg body weight per day of CNPs 
that was administrated orally.58 In contrast, cerium oxide 
was toxic to bronchial epithelial lung fibroblasts in culture,59 
but non-toxic to mammary epithelial cells,60 macrophages,61 
immortalized keratinocytes,62 or immortalized pancreatic 
epithelial cells.56 They are not toxic in normal cells, while the 
physiological pH is suitable for enabling canonical radical 
scavenging by CNPs.63,64
Conclusion
Based on the findings demonstrated here, it was found that 
pullulan-mediated CNPs is safe following acute adminis-
tration. In this work the safety and antioxidant ability of 
CNPs have been studied by evaluating several markers 
of serum oxidative stress, hematological parameters, and 
some liver enzymes. It could be concluded that CNPs have 
no damage to liver enzymes, liver, and renal tissues. CNPs 
seem safe to be used for medical applications and have a 
protective behavior against the oxidative stress. Of course, 
further studies, including more doses, are required to 
prove its safety in subacute/chronic situations. At the same 
time, further research studies should also be performed on 
pullulan-mediated CNPs to further develop its potential as an 
effective antioxidant for the management of illnesses caused 
by uncontrolled oxidative stress.
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Figure S1 FTIr of cNPs.
Abbreviation: cNP, cerium oxide nanoparticle.
Figure S2 FeseM image of cNPs.
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Figure S3 XrD pattern of cNPs.
Abbreviations: cNP, cerium oxide nanoparticle; XrD, X-ray diffraction.
Figure S4 MTT assay of cNPs.
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